{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:16:49Z","timestamp":1747196209470,"version":"3.40.5"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Objective<\/jats:title><jats:p>To describe differences by race and ethnicity in treatment patterns among hospitalized COVID-19 patients in the US from March-August 2020.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>Among patients in de-identified Optum electronic health record data hospitalized with COVID-19 (March-August 2020), we estimated odds ratios of receiving COVID-19 treatments of interest (azithromycin, dexamethasone, hydroxychloroquine, remdesivir, and other steroids) at hospital admission, by race and ethnicity, after adjusting for key covariates of interest.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>After adjusting for key covariates, Black\/African American patients were less likely to receive dexamethasone (adj. OR [95% CI]: 0.83 [0.71, 0.96]) and more likely to receive other steroids corticosteroids (adj. OR [95% CI]: 2.13 [1.90, 2.39]), relative to White patients. Hispanic\/Latino patients were less likely to receive dexamethasone than Not Hispanic\/Latino patients (adj. OR [95% CI]: 0.69 [0.58, 0.82]).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>Our findings suggest that COVID-19 treatments patients received in Optum varied by race and ethnicity after adjustment for other possible explanatory factors. In the face of rapidly evolving treatment landscapes, policies are needed to ensure equitable access to novel and repurposed therapeutics to avoid disparities in care by race and ethnicity.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0267815","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:46:14Z","timestamp":1664214374000},"page":"e0267815","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3466-9928","authenticated-orcid":true,"given":"Sarah E.","family":"Vititoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imaani J.","family":"Easthausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Lasky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-3053","authenticated-orcid":true,"given":"Aloka","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolle M.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Weckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-1599","authenticated-orcid":true,"given":"Elizabeth M.","family":"Garry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"pone.0267815.ref001","unstructured":"CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Apr 23]. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"pone.0267815.ref002","unstructured":"A Timeline of COVID-19 Developments in 2020 [Internet]. AJMC. [cited 2021 Jul 19]. Available from: https:\/\/www.ajmc.com\/view\/a-timeline-of-covid19-developments-in-2020"},{"key":"pone.0267815.ref003","unstructured":"U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Disparities. [Internet]. Healthy People 2020. 2014 [cited 2021 Jul 19]. Available from: https:\/\/www.healthypeople.gov\/2020\/about\/foundation-health-measures\/Disparities"},{"key":"pone.0267815.ref004","unstructured":"CDC. Health Equity Considerations and Racial and Ethnic Minority Groups [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Jul 19]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/community\/health-equity\/race-ethnicity.html"},{"key":"pone.0267815.ref005","unstructured":"CDC. Risk for COVID-19 Infection, Hospitalization, and Death By Race\/Ethnicity [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Jul 19]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-race-ethnicity.html"},{"key":"pone.0267815.ref006","article-title":"Coronavirus Disease 2019 Case Surveillance\u2014United States, January 22\u2013May 30, 2020.","author":"EK Stokes","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0267815.ref007","article-title":"Characteristics Associated with Hospitalization Among Patients with COVID-19\u2014Metropolitan Atlanta, Georgia, March\u2013April 2020.","author":"ME Killerby","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"pone.0267815.ref008","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-6306","article-title":"Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review","volume":"174","author":"K Mackey","year":"2021","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0267815.ref009","doi-asserted-by":"crossref","first-page":"e2018039","DOI":"10.1001\/jamanetworkopen.2020.18039","article-title":"Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals.","volume":"3","author":"BR Yehia","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0267815.ref010","article-title":"Characteristics and Factors Associated With Coronavirus Disease 2019 Infection, Hospitalization, and Mortality Across Race and Ethnicity.","author":"CL Dai","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0267815.ref011","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","article-title":"Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET).","volume":"72","author":"L Kim","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"3","key":"pone.0267815.ref012","doi-asserted-by":"crossref","first-page":"e0248128","DOI":"10.1371\/journal.pone.0248128","article-title":"COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.","volume":"16","author":"M Stewart","year":"2021","journal-title":"PLOS ONE."},{"issue":"9","key":"pone.0267815.ref013","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1002\/jmv.27049","article-title":"Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement","volume":"93","author":"JH Best","year":"2021","journal-title":"J Med Virol"},{"key":"pone.0267815.ref014","doi-asserted-by":"crossref","first-page":"102725","DOI":"10.1016\/j.msard.2020.102725","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis.","volume":"49","author":"R Hughes","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"pone.0267815.ref015","doi-asserted-by":"crossref","unstructured":"EM Garry. Use of an EHR to inform a claims-based algorithm to categorize inpatient COVID-19 severity. Podium presented at; 2021 Aug; Virtual.","DOI":"10.1101\/2021.10.04.21264513"},{"key":"pone.0267815.ref016","unstructured":"Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity [Internet]. The White House. [cited 2021 Jul 19]. Available from: https:\/\/obamawhitehouse.archives.gov\/node\/15626"},{"issue":"7","key":"pone.0267815.ref017","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index","volume":"73","author":"DH Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"11","key":"pone.0267815.ref018","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care.Nov"},{"issue":"6","key":"pone.0267815.ref019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries","volume":"173","author":"H Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"pone.0267815.ref020","unstructured":"CDC. Coronavirus Disease 2019 (COVID-19)\u2013Symptoms [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Jul 19]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"pone.0267815.ref021","doi-asserted-by":"crossref","unstructured":"EM Garry, AR Weckstein, K Quinto, MC Bradley, T Lasky, S Leonard, et al. Categorization of COVID-19 severity to determine mortality risk. Podium presented at; 2021 Aug; Virtual.","DOI":"10.1002\/pds.5436"},{"key":"pone.0267815.ref022","unstructured":"Bradley MC, Garry EM, Weckstein AR, Quinto K, Lasky T, Leonard S, et al. Categorization of COVID-19 severity to determine mortality risk. Poster presented at;"},{"key":"pone.0267815.ref023","article-title":"Use of an EHR to inform an administrative data algorithm to categorize inpatient COVID-19 severity.","author":"EM Garry","year":"2021","journal-title":"medRxiv"},{"issue":"1","key":"pone.0267815.ref024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching.","volume":"7","author":"Z Zhang","year":"2019","journal-title":"Ann Transl Med."},{"issue":"3","key":"pone.0267815.ref025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cpt.329","article-title":"Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases","volume":"99","author":"S Wang","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"pone.0267815.ref026","unstructured":"Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM [Internet]. [cited 2021 Jul 19]. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2022926"},{"issue":"6","key":"pone.0267815.ref027","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"journal-title":"Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate","year":"2020","author":"U.S. Food and Drug Administration","key":"pone.0267815.ref028"},{"issue":"10274","key":"pone.0267815.ref029","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"397","author":"E Abaleke","year":"2021","journal-title":"The Lancet"},{"key":"pone.0267815.ref030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022926","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","author":"The RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"pone.0267815.ref031","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2020","journal-title":"JAMA"},{"key":"pone.0267815.ref032","unstructured":"Perez-Vilar, Silvia, FDA\/OSE; Weckstein, Andrew, Aetion, Inc; Vititoe, Sarah, Aetion, Inc; Rivera, Donna R., FDA\/OCE; Bradley, Marie C., FDA\/OSE; Leonard, Sandy, et al. Temporal Trends in Medication Utilization Among Hospitalized COVID-19 Patients in the United States [Internet]. FDA. FDA; 2021 [cited 2021 Jul 19]. Available from: https:\/\/www.fda.gov\/science-research\/fda-science-forum\/temporal-trends-medication-utilization-among-hospitalized-covid-19-patients-united-states"},{"key":"pone.0267815.ref033","unstructured":"AR Weckstein, S Vititoe, DR Rivera, MC Bradley, S Perez-Vilar, S Leonard, et al. Temporal trends in medication utilization among hospitalized COVID-19 patients. Poster presented at; 2021 Aug; Virtual."},{"issue":"6","key":"pone.0267815.ref034","doi-asserted-by":"crossref","first-page":"e2112842","DOI":"10.1001\/jamanetworkopen.2021.12842","article-title":"Patient and Hospital Factors Associated With Differences in Mortality Rates Among Black and White US Medicare Beneficiaries Hospitalized With COVID-19","volume":"4","author":"DA Asch","year":"2021","journal-title":"Infection. JAMA Netw Open"},{"issue":"15","key":"pone.0267815.ref035","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMp2107331","article-title":"Integrating Research into Community Practice\u2014Toward Increased Diversity in Clinical Trials","volume":"385","author":"J Woodcock","year":"2021","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T19:20:42Z","timestamp":1701112842000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267815"}},"subtitle":[],"editor":[{"given":"Sinan","family":"Karde\u015f","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267815","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}